Klaus Langohr

Dr. Klaus Langohr

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in The Lancet Neurology
Verified
Journal Article
Open access
Renato TorreRenato Torre
Renato Torre
SSSusana de Sola
Susana de Sola
GHGimena Hernandez
Gimena Hernandez
MFMagí Farré
Magí Farré
JPJesus Pujol
Jesus Pujol
MDMara Dierssen
Mara Dierssen
Early cognitive intervention is the only routine therapeutic approach used for amelioration of intellectual deficits in individuals with Down's syndrome, but its effects are limited. We hypothesised that administration of a green tea extract containing epigallocatechin-3-gallate (EGCG) would improve the effects of non-pharmacological cognitive rehabilitation in young adults with Down's syndrome. We enrolled adults (aged 16-34 years) with Down's syndrome from outpatient settings in Catalonia, Spain, with any of the Down's syndrome genetic variations (trisomy 21, partial trisomy, mosaic, or translocation) in a double-blind, placebo-controlled, phase 2, single centre trial (TESDAD). Participants were randomly assigned at the IMIM-Hospital del Mar Medical Research Institute to receive EGCG (9 mg/kg per day) or placebo and cognitive training for 12 months. We followed up participants for 6 months after treatment discontinuation. We randomly assigned participants using random-number tables and balanced allocation by sex and intellectual quotient. Participants, families, and researchers assessing the participants were masked to treatment allocation. The primary endpoint was cognitive improvement assessed by neuropsychologists with a battery of cognitive tests for episodic memory, executive function, and functional measurements. Analysis was on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01699711. The study was done between June 5, 2012, and June 6, 2014. 84 of 87 participants with Down's syndrome were included in the intention-to-treat analysis at 12 months (43 in the EGCG and cognitive training group and 41 in the placebo and cognitive training group). Differences between the groups were not significant on 13 of 15 tests in the TESDAD battery and eight of nine adaptive skills in the Adaptive Behavior Assessment System II (ABAS-II). At 12 months, participants treated with EGCG and cognitive training had significantly higher scores in visual recognition memory (Pattern Recognition Memory test immediate recall, adjusted mean difference: 6·23 percentage points [95% CI 0·31 to 12·14], p=0·039; d 0·4 [0·05 to 0·84]), inhibitory control (Cats and Dogs total score, adjusted mean difference: 0·48 [0·02 to 0·93], p=0·041; d 0·28 [0·19 to 0·74]; Cats and Dogs total response time, adjusted mean difference: -4·58 s [-8·54 to -0·62], p=0·024; d -0·27 [-0·72 to -0·20]), and adaptive behaviour (ABAS-II functional academics score, adjusted mean difference: 5·49 [2·13 to 8·86], p=0·002; d 0·39 [-0·06 to 0·84]). No differences were noted in adverse effects between the two treatment groups. EGCG and cognitive training for 12 months was significantly more effective than placebo and cognitive training at improving visual recognition memory, inhibitory control, and adaptive behaviour. Phase 3 trials with a larger population of individuals with Down's syndrome will be needed to assess and confirm the long-term efficacy of EGCG and cognitive training. Jérôme Lejeune Foundation, Instituto de Salud Carlos III FEDER, MINECO, Generalitat de Catalunya.

15 August 2012 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
MUMarc Udina
Marc Udina
PCPere Castellvi
Pere Castellvi
JMJosé Moreno-España
José Moreno-España
RNRicard Navinés
Ricard Navinés
MVManuel Valdés
Manuel Valdés
RMRocío Martín-Santos
Rocío Martín-Santos
From The Journal of Clinical Psychiatry:

14 September 2013 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
Renato TorreRenato Torre
Renato Torre
SSSusana De Sola
Susana De Sola
MPMeritxell Pons
Meritxell Pons
ADArnaud DUCHON
Arnaud DUCHON
MLMaria Martinez de Lagran
Maria Martinez de Lagran
MDMara Dierssen
Mara Dierssen

12 September 2012 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
RMR. Martin-Santos
R. Martin-Santos
JCJ. A. Crippa
J. A. Crippa
ABAlbert Batalla
Albert Batalla
SBSagnik Bhattacharyya
Sagnik Bhattacharyya
ZAZ. Atakan
Z. Atakan
PMP. K. McGuire
P. K. McGuire
Rationale: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. Objective: To evaluate and compare the acute pharmacological effects of both THC and CBD in the same human volunteers. Methods: A randomised, double-blind, cross-over, placebo controlled trial was conducted in 16 healthy male subjects. Oral THC 10 mg or CBD 600 mg or placebo was administered in three consecutive sessions, at one-month interval. Physiological measures and symptom ratings were assessed before, and at 1, 2 and 3 hours post drug administration. The area under the curve (AUC) between baseline and 3 hours, and the maximum absolute change from baseline at 2 hours were analysed by one-way repeated measures analysis of variance, with drug condition (THC or CBD or placebo) as the factor. Results: Relative to both placebo and CBD, administration of THC was associated with anxiety, dysphoria, positive psychotic symptoms, physical and mental sedation, subjective intoxication (AUC and effect at 2 hours: p<0.01), an increase in heart rate (p<0.05). There were no differences between CBD and placebo on any symptomatic, physiological variable. Conclusions: In healthy volunteers, THC has marked acute behavioural and physiological effects, whereas CBD has proven to be safe and well tolerated.

1 January 2003 in Journal of Food Science
Verified
Journal Article
Closed access
PDF file
GHG. Hough
G. Hough
KLKlaus Langohr
Klaus Langohr
GGGuadalupe Gómez
Guadalupe Gómez
ACA. Curia
A. Curia

17 December 2009 in Statistical Modelling
Verified
Journal Article
Closed access
GGGuadalupe Gómez
Guadalupe Gómez
MCM Luz Calle
M Luz Calle
RORamon Oller
Ramon Oller
KLKlaus Langohr
Klaus Langohr
Interval censoring is encountered in many practical situations when the event of interest cannot be observed and it is only known to have occurred within a time window. The theory for the analysis of interval-censored data has been developed over the past three decades and several reviews have been written. However, it is still a common practice in medical and reliability studies to simplify the interval censoring structure of the data into a more standard right censoring situation by, for instance, imputing the midpoint of the censoring interval. The availability of software for right censoring might well be the main reason for this simplifying practice. In contrast, several methods have been developed to deal with interval-censored data and the corresponding algorithms to make the procedures feasible are scattered across the statistical software or remain behind the personal computers of many researchers. The purpose of this tutorial is to present, in a pedagogical and unified manner, the methodology and the available software for analyzing interval-censored data. The paper covers frequentist non-parametric, parametric and semiparametric estimating approaches, non-parametric tests for comparing survival curves and a section on simulation of interval-censored data. The methods and the software are described using the data from a dental study.